Open AccessModeling the heart with Novoheart’s MyHeart™ platform
Author(s) -
G.C. Wong,
Kevin D. Costa,
Bernard Fermini,
Ronald A Li
Publication year - 2020
Publication title -
future drug discovery
Language(s) - English
Resource type - Journals
ISSN - 2631-3316
DOI - 10.4155/fdd-2020-0003
Subject(s) - human heart , induced pluripotent stem cell , computer science , computational biology , function (biology) , human use , in vitro , biomedical engineering , neuroscience , biology , medicine , microbiology and biotechnology , embryonic stem cell , biochemistry , gene
Reliable and predictive human-specific in vitro heart models can revolutionize drug discovery and development. With the advent of pluripotent stem cell technologies, human cardiomyocytes can now be readily produced in large quantities. Using tissue engineering techniques, they can be further assembled into cardiac tissues of specific 2D and 3D configurations, to create models that behave and function like the native human heart. Novoheart (BC, Canada) uniquely offers the MyHeart TM Platform of bioengineered human heart constructs, designed to provide researchers with effective models of either healthy or diseased human hearts. As in vitro, human-based assays become more widely accepted, the next decade could witness a shift away from animal testing towards more accurate and scalable human assays like the MyHeart TM Platform.